View Older Stories View More Recent Stories

Mar 8, 2023 08:10AM Esperion Therapeutics (ESPR) Announces ILEP Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
Mar 8, 2023 08:00AM International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
Mar 8, 2023 08:00AM International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
Mar 6, 2023 05:53AM Esperion Therapeutics (ESPR) Reports CLEAR Outcomes Study Demonstrates NEXLETOL Tablet is the Only LDL-C Lowering Therapy
Mar 4, 2023 10:30AM Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prev
Mar 4, 2023 10:30AM Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prev
Feb 24, 2023 01:40PM Esperion Launches New Scientific Website
Feb 23, 2023 08:00AM Esperion to Participate in the Cowen 43rd Annual Healthcare Conference
Feb 23, 2023 08:00AM Esperion to Participate in the Cowen 43rd Annual Healthcare Conference
Feb 22, 2023 08:00AM CLEAR Outcomes Company Update Call: Detailed Results Discussion
Feb 22, 2023 08:00AM CLEAR Outcomes Company Update Call: Detailed Results Discussion
Feb 21, 2023 07:00AM Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
Feb 21, 2023 07:00AM Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
Feb 20, 2023 08:00AM Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
Feb 20, 2023 08:00AM Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
Feb 13, 2023 04:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 13, 2023 04:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 7, 2023 08:00AM Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
Feb 7, 2023 08:00AM Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
Jan 11, 2023 11:00AM RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
Jan 9, 2023 05:04AM Esperion Therapeutics (ESPR) Reports Prelim Q4 Revenue of $14.4M-$15.1M, Outlines Upcoming Milestones
Jan 8, 2023 07:00PM Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
Jan 8, 2023 07:00PM Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
Dec 19, 2022 04:15PM CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
Dec 19, 2022 04:15PM CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
Dec 13, 2022 06:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 13, 2022 06:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 13, 2022 08:00AM Esperion to Participate in January Investor Meetings
Dec 13, 2022 08:00AM Esperion to Participate in January Investor Meetings
Dec 7, 2022 08:05AM Esperion Therapeutics (ESPR) Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL Meets Primary Endpoint
Dec 7, 2022 08:05AM Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
Dec 7, 2022 08:05AM Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
Nov 16, 2022 04:00PM Esperion Therapeutics (ESPR) Appoints Ben Halladay as CFO
Nov 16, 2022 04:00PM Esperion Appoints Ben Halladay Chief Financial Officer
Nov 16, 2022 04:00PM Esperion Appoints Ben Halladay Chief Financial Officer
Nov 9, 2022 08:00AM Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
Nov 9, 2022 08:00AM Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
Nov 2, 2022 08:00AM Esperion to Participate in Jefferies London Healthcare Conference
Nov 2, 2022 08:00AM Esperion to Participate in Jefferies London Healthcare Conference
Nov 1, 2022 07:00AM Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update
Nov 1, 2022 07:00AM Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update
Oct 27, 2022 08:00AM Esperion Hosting Virtual Research & Development Day
Oct 27, 2022 08:00AM Esperion Hosting Virtual Research & Development Day
Oct 19, 2022 04:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 19, 2022 04:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 17, 2022 08:02AM Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
Oct 17, 2022 08:02AM Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
Aug 30, 2022 08:00AM Esperion to Participate in Upcoming September Investor Conferences
Aug 30, 2022 08:00AM Esperion to Participate in Upcoming September Investor Conferences
Aug 26, 2022 08:21AM Esperion Therapeutics (ESPR) Announces NEXLETOL Recommended as Oral Non-Statin Therapy for LDL-Cholesterol
View More Recent Stories View Older Stories